Rethinking the metastatic cascade as a therapeutic target

Nature Reviews Clinical Oncology

Volumn 8, Issue 6, 2011, Pages 325-332

  Mina, Lida A ^a   Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; DENOSUMAB; VASCULOTROPIN INHIBITOR; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOLOGY; CANCER STEM CELL; CLINICAL TRIAL (TOPIC); DRUG MONITORING; DRUG SAFETY; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; METASTASIS; METASTASIS PROMOTER GENE; METASTASIS SUPPRESSOR GENE; METASTATIC COLONIZATION; MICROMETASTASIS; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROMOTER REGION; SUPPRESSOR GENE; TREATMENT DURATION; TUMOR DORMANCY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 85027930332     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.59     Document Type: Article

References (100)

1. Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539-1544 (2007). (Pubitemid 46733080)
2. Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11-16 (2011).
3. Van Cutsem, E., Lambrechts, D., Prenen, H., Jain, R. K. & Carmeliet, P. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J. Clin. Oncol. 29, 1-4 (2011).
4. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000). (Pubitemid 30046295)
5. Kerbel, R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21, 505-515 (2000). (Pubitemid 30137936)
6. Leenders, W. P., Kusters, B. & de Waal, R. M. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 9, 83-87 (2002). (Pubitemid 35252016)
7. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
8. Ebos, J. M. & Kerbel, R. S. Antiangiogenic therapy: impact on invasion, disease progression and metastasis. Nat. Rev. Clin. Oncol. 8, 210-221 (2011).
9. Berger, J. C., Vander Griend, D. J., Robinson, V. L., Hickson, J. A. & Rinker-Schaeffer, C. W. Metastasis suppressor genes: from gene identification to protein function and regulation. Cancer Biol. Ther. 4, 805-812 (2005).
10. Ma, L. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341-347 (2010).
11. Palmieri, D. et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA doublestrand breaks. Clin. Cancer Res. 15, 6148-6157 (2009).
12. Chambers, A. F., MacDonald, I. C., Schmidt, E. E., Morris, V. L. & Groom, A. C. Clinical targets for anti-metastasis therapy. Adv. Cancer Res. 79, 91-121 (2000).
13. Steeg, P. S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12, 895-904 (2006). (Pubitemid 44175140)
14. Weiss, L., Ward, P. M. & Holmes, J. C. Liver-to-lung traffic of cancer cells. Int. J. Cancer 32, 79-83 (1983). (Pubitemid 13032540)
15. Weiss, L., Voit, A. & Lane, W. W. Metastatic patterns in patients with carcinomas of the lower esophagus and upper rectum. Invasion Metastasis 4, 47-60 (1984). (Pubitemid 14168895)
16. Weiss, L. et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J. Pathol. 150, 195-203 (1986). (Pubitemid 17181753)
17. Ma, L., Teruya-Feldstein, J. & Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682-688 (2007). (Pubitemid 47552092)
18. Palmieri, D. et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J. Natl Cancer Inst. 97, 632-642 (2005).
19. Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284 (2009).
20. Taylor, J. L. et al. New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett. 272, 12-22 (2008).
21. Guise, T. A. et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 12, 6213s-6216s (2006). (Pubitemid 44703792)
22. Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593 (2002). (Pubitemid 37328925)
23. Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009).
24. Coleman, R. E. et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04) [abstract S4-5]. 70 (24 Suppl.), 86s (2010).
25. Fizazi, K. et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 27, 1564-1571 (2009).
26. Lipton, A. et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol. 25, 4431-4437 (2007). (Pubitemid 350013849)
27. US National Library of Medicine. ClinicalTrials. gov [online], http://clinicaltrials.gov/ct2/show/NCT01077154 (2011).
28. Sossey-Alaoui, K. et al. Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells. Am. J. Pathol. 170, 2112-2121 (2007). (Pubitemid 47339283)
29. Steeg, P. S., Bevilacqua, G., Pozzatti, R., Liotta, L. A. & Sobel, M. E. Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Res. 48, 6550-6554 (1988).
30. Smith, S. C. & Theodorescu, D. Learning therapeutic lessons from metastasis suppressor proteins. Nat. Rev. Cancer 9, 253-264 (2009).
31. Marshall, J. C., Lee, J. H. & Steeg, P. S. Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. Mol. Cell Biochem. 329, 115-120 (2009).
32. US National Library of Medicine. ClinicalTrials. gov [online], http://clinicaltrials.gov/ct2/show/NCT00577122 (2010).
33. Titus, B. et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res. 65, 7320-7327 (2005). (Pubitemid 41161264)
34. Said, N., Smith, S., Sanchez-Carbayo, M. & Theodorescu, D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J. Clin. Invest. 121, 132-147 (2011).
35. Dykxhoorn, D. M. MicroRNAs and metastasis: little RNAs go a long way. Cancer Res. 70, 6401-6406 (2010).
36. Gumireddy, K. et al. In vivo selection for metastasis promoting genes in the mouse. Proc. Natl Acad. Sci. USA 104, 6696-6701 (2007). (Pubitemid 47175563)
37. Armeanu-Ebinger, S. et al. Differential expression of invasion promoting genes in childhood rhabdomyosarcoma. Int. J. Oncol. 38, 993-1000 (2011).
38. Folkman, J. & Klagsbrun, M. Angiogenic factors. Science 235, 442-447 (1987). (Pubitemid 17009577)
39. Bishop, G. A. & Hostager, B. S. Molecular mechanisms of CD40 signaling. Arch. Immunol. Ther. Exp. (Warsz.) 49, 129-137 (2001). (Pubitemid 33613657)
40. Conway, E. M., Collen, D. & Carmeliet, P. Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49, 507-521 (2001). (Pubitemid 32146414)
41. Gale, N. W. & Yancopoulos, G. D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 13, 1055-1066 (1999). (Pubitemid 29233137)
42. Nelson, A. R., Fingleton, B., Rothenberg, M. L. & Matrisian, L. M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 18, 1135-1149 (2000). (Pubitemid 30123793)
43. Carmeliet, P. Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries: a goal for therapeutic angiogenesis? Circ. Res. 87, 176-178 (2000). (Pubitemid 30626422)
44. Lindahl, P. et al. Role of platelet-derived growth factors in angiogenesis and alveogenesis. Curr. Top. Pathol. 93, 27-33 (1999).
45. Loges, S., Mazzone, M., Hohensinner, P. & Carmeliet, P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15, 167-170 (2009).
46. Ellis, L. M. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin. Oncol. 33, S1-S7 (2006). (Pubitemid 44634008)
47. Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
48. Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
49. Schneider, B. P. & Sledge, G. W. Jr. Anti-VEGF therapy as adjuvant therapy: clouds on the horizon? Breast Cancer Res. 11, 303 (2009).
50. Kim, D. W., Lu, B. & Hallahan, D. E. Receptor tyrosine kinase inhibitors as anti-angiogenic agents. Curr. Opin. Investig. Drugs 5, 597-604 (2004).
51. Karin, M. Nuclear factor-κB in cancer development and progression. Nature 441, 431-436 (2006). (Pubitemid 44050137)
52. Karin, M., Yamamoto, Y. & Wang, Q. M. The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3, 17-26 (2004). (Pubitemid 38088695)
53. Rosenberg, S. A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913 (1994).
54. Coppin, C. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (1):CD001425 (2005).
55. Liu, B., DeFilippo, A. M. & Li, Z. Overcoming immune tolerance to cancer by heat shock protein vaccines. Mol. Cancer Ther. 1, 1147-1151 (2002).
56. Seavey, M. M. et al. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin. Cancer Res. 15, 924-932 (2009).
57. Holmes, J. P. et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J. Clin. Oncol. 26, 3426-3433 (2008).
58. Pichichero, M. E. Improving vaccine delivery using novel adjuvant systems. Hum. Vaccin. 4, 262-270 (2008).
59. Hodi, F. S. Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res. 13, 5238-5242 (2007). (Pubitemid 47510345)
60. Demicheli, R., Abbattista, A., Miceli, R., Valagussa, P. & Bonadonna, G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res. Treat. 41, 177-185 (1996). (Pubitemid 26360147)
61. Karrison, T. G., Ferguson, D. J. & Meier, P. Dormancy of mammary carcinoma after mastectomy. J. Natl Cancer Inst. 91, 80-85 (1999). (Pubitemid 29042447)
62. Vessella, R. L., Pantel, K. & Mohla, S. Tumor cell dormancy: an NCI workshop report. Cancer Biol. Ther. 6, 1496-1504 (2007). (Pubitemid 351590364)
63. Stearns, A. T., Hole, D., George, W. D. & Kingsmore, D. B. Comparison of breast cancer mortality rates with those of ovarian and colorectal carcinoma. Br. J. Surg. 94, 957-965 (2007). (Pubitemid 47236539)
64. Saphner, T., Tormey, D. C. & Gray, R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 14, 2738-2746 (1996). (Pubitemid 26329660)
65. Willis, L. et al. Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res. 70, 4310-4317 (2010).
66. Townson, J. L. & Chambers, A. F. Dormancy of solitary metastatic cells. Cell Cycle 5, 1744-1750 (2006). (Pubitemid 44435316)
67. Naumov, G. N. et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res. Treat. 82, 199-206 (2003). (Pubitemid 37521976)
68. Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907 (2007). (Pubitemid 350231320)
69. Aguirre-Ghiso, J. A., Estrada, Y., Liu, D. & Ossowski, L. ERK (MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38 (SAPK). Cancer Res. 63, 1684-1695 (2003). (Pubitemid 36373662)
70. Aguirre-Ghiso, J. A., Ossowski, L. & Rosenbaum, S. K. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res. 64, 7336-7345 (2004). (Pubitemid 39372072)
71. Barkan, D. et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 68, 6241-6250 (2008).
72. Goss, P. E. & Chambers, A. F. Does tumour dormancy offer a therapeutic target? Nat. Rev. Cancer 10, 871-877 (2010).
73. Maitland, N. J. & Collins, A. T. Cancer stem cells - a therapeutic target? Curr. Opin. Mol. Ther. 12, 662-673 (2010).
74. Patel, S. A., Ndabahaliye, A., Lim, P. K., Milton, R. & Rameshwar, P. Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer (London) 2, 1-11 (2010).
75. Takebe, N., Harris, P. J., Warren, R. Q. & Ivy, S. P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 8, 97-106 (2011).
76. Von Hoff, D. D. et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164-1172 (2009).
77. Rudin, C. M. et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361, 1173-1178 (2009).
78. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01158404 (2010).
79. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00106145 (2011).
80. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00256334 (2009).
81. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00002864 (2010).
82. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00002967 (2008).
83. Miller, K. D. et al. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann. Oncol. 13, 1220-1224 (2002). (Pubitemid 34960130)
84. Miller, K. D. et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin. Cancer Res. 10, 1971-1975 (2004). (Pubitemid 38375555)
85. Pegram, M. D., Pietras, R., Bajamonde, A., Klein, P. & Fyfe, G. Targeted therapy: wave of the future. J. Clin. Oncol. 23, 1776-1781 (2005). (Pubitemid 46211429)
86. 64. Cancer Res. 61, 4966-4970 (2001). (Pubitemid 32681519)
87. Branca, R. T. et al. Molecular MRI for sensitive and specific detection of lung metastases. Proc. Natl Acad. Sci. USA 107, 3693-3697 (2010).
88. Maitland, M. L., Hudoba, C., Snider, K. L. & Ratain, M. J. Analysis of the yield of phase II combination therapy trials in medical oncology. Clin. Cancer Res. 16, 5296-5302 (2010).
89. Pantel, K., Alix-Panabieres, C. & Riethdorf, S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 6, 339-351 (2009).
90. Pantel, K. & Riethdorf, S. Pathology: are circulating tumor cells predictive of overall survival? Nat. Rev. Clin. Oncol. 6, 190-191 (2009).
91. Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793-802 (2005). (Pubitemid 41215488)
92. Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152-8162 (2004). (Pubitemid 40053373)
93. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01074970 (2011).
94. De Gramont, A. et al. AVANT: Results from randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer [abstract]. J. Clin. Oncol. 29 (Suppl. 4), a362 (2011).
95. Goss, P. E. et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97, 1262-1271 (2005). (Pubitemid 41535367)
96. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00754845 (2010).
97. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00003016 (2009).
98. Ciuleanu, T. et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374, 1432-1440 (2009).
99. Sargent, D. J. & Hayes, D. F. Assessing the measure of a new drug: is survival the only thing that matters? J. Clin. Oncol. 26, 1922-1923 (2008).
100. Cortazar, P., Johnson, R., Justice, R. et al. Adjuvant breast cancer: FDA approval overview [abstract]. J. Clin. Oncol. 27 (Suppl.), e11529 (2009).